The demo accomplished the two its Major endpoints, with semaglutide 2.4 mg demonstrating statistically major and remarkable enhancements in liver fibrosis without worsening of steatohepatitis, in addition to resolution of steatohepatitis without worsening of liver fibrosis in those with MASH compare